Pituitary Gland
Anatomical Feature of Nasal Cavity for Endoscopic Endonasal Skull Base Surgery in Patients With GHoma.
Suzuki T, et al
A retrospective CT analysis comparing 28 growth hormone-secreting pituitary adenoma (GHoma) patients with 104 non-GHoma pituitary neuroendocrine tumor (PitNET) patients found that GHoma patients have significantly larger nasolacrimal duct opening width, piriform aperture width, and anterior nasal sp…
Source →What do you mean by PitNETs in WHO Classification 2022?
Osamura RY, et al
The 2022 WHO Classification formally reclassifies pituitary adenomas as „pituitary neuroendocrine tumours" (PitNETs), recognizing them as potentially aggressive neoplasms capable of invasion and metastasis, analogous to pancreatic neuroendocrine tumours. PitNETs are now categorized according to the …
Source →Spontaneous remission of Cushing disease after clinically silent pituitary apoplexy with persistent positive desmopressin stimulation.
Witek K, et al
A patient with Cushing disease achieved spontaneous remission following a clinically silent pituitary apoplexy, a hemorrhagic or ischemic infarction event occurring within the ACTH-secreting pituitary adenoma that produced no overt symptoms at the time it occurred. Despite confirmed biochemical remi…
Source →Long term neuropsychological evaluation of adult patients with craniopharyngiomas.
Guillotin J, et al
A long-term neuropsychological study of 22 adult craniopharyngioma patients found that more than 65% experienced at least one impairment in executive functioning — particularly cognitive inhibition deficits or difficulties with organization — after treatment involving surgery and sometimes radiother…
Source →Importance of clinical profiling to determine excess mortality in prolactinomas: insights from a large, registry-based cohort.
Shwaish TZ, et al
A registry-based cohort study of 3,378 adults with prolactinoma (26,118 person-years; SEER database, 2004–2022) found significant overall excess all-cause mortality (SMR 1.21, 95% CI 1.03–1.41), but unsupervised clustering revealed that this risk is highly unequal across two distinct patient profile…
Source →Internal validation of THINKERS-PA for outcome prediction after pituitary adenoma radiosurgery.
Reyes JS, et al
THINKERS-PA, a mixture-of-experts (MoE) neural network framework for individualized outcome prediction after Gamma Knife radiosurgery (GKRS) for pituitary adenomas, achieved strong internally validated performance with mean out-of-fold time-dependent AUCs of 0.82 for tumor progression, 0.84 for bioc…
Source →Exploring the SPARAGMOS Study Protocol: review of a high-dose cabergoline interventional trial in microprolactinomas.
Stumpf MA, et al
The SPARAGMOS trial (NCT07463235) proposes that approximately 6 months of high-dose cabergoline therapy can achieve a remission rate of approximately 70% in microprolactinoma patients — matching outcomes reported for transsphenoidal neurosurgery in specialized pituitary centers — compared with the a…
Source →Radiomics and artificial intelligence in pituitary adenomas (PitNETs): from imaging biomarkers to clinical translation.
Ruiz S, et al
A narrative review of studies published between 2019 and 2025 finds that MRI-based radiomics and artificial intelligence hold strong promise for transforming the clinical management of pituitary neuroendocrine tumors (PitNETs), with texture- and shape-based features from T2-weighted and multiparamet…
Source →ROBO1 is required for postnatal growth and survival.
Kirk NA, et al
Mice lacking the ROBO1 gene on a mixed B6/129S genetic background survive into adulthood and exhibit a broad range of previously unreported abnormalities, including stunted growth, enlarged lung alveoli, premature hair graying, diminished subcutaneous fat, and a reduced lifespan. At 23 days of age —…
Source →Thyroid-stimulating hormone-secreting pituitary neuroendocrine tumor (TSH-PitNet) diagnosed during pregnancy and treated with a somatostatin analog.
Kawabata I, et al
A case report from the Taiwanese Journal of Obstetrics & Gynecology demonstrates that a conservative management strategy using monthly lanreotide injections from 18 weeks of gestation until term can achieve safe outcomes for both mother and infant in the extremely rare setting of a TSH-secreting pit…
Source →ARGININE VASOPRESSIN DEFICIENCY: TOWARDS A BETTER CHARACTERIZATION.
Atila C, et al
A comprehensive review published in Endocrine-related cancer outlines an updated diagnostic and therapeutic framework for arginine vasopressin (AVP) deficiency — a condition formerly known as central diabetes insipidus — characterized by impaired AVP synthesis or secretion from the hypothalamus or p…
Source →High-contrast somatostatin receptor imaging of meningiomas with [¹⁸F]SiTATE PET/CT.
Sachpekidis C, et al
A novel fluorine-18-labeled PET tracer, [¹⁸F]SiTATE, demonstrated high-contrast visualization of meningiomas in 32 of 37 patients (86.5%), identifying 69 lesions in total with intense tumor uptake (SUVmax 20.44 ± 14.54; SUVpeak 12.10 ± 8.04) and minimal normal brain background activity (SUVmax 0.11 …
Source →Capturing fine-grained spatial details in brain tumor MRI via multi-module feature enhancement.
Chen J, et al
A novel deep learning framework called FDANet achieved a mean average precision (mAP50) of 0.961 in MRI-based detection of brain tumors — including pituitary adenomas, gliomas, and meningiomas — representing a 6.0 percentage point improvement over the baseline YOLOv11 model while maintaining low par…
Source →Emerging insights into the pathophysiology of pituitary tumour microenvironment.
Fuentes-Fayos AC, et al
A new review published in Endocrine-Related Cancer underscores that pituitary tumours (PiTs) are far more common than widely assumed, accounting for at least 15% of all intracranial tumours, while their profound intra- and inter-patient heterogeneity has long constrained our understanding of the mec…
Source →A long-acting octreotide analog formed by conjugation with a peptide linker modified with two fatty acids.
Yu Y, et al
A novel depot-free octreotide analog, TE-8214, demonstrated sustained pharmacodynamic activity and favorable tolerability in a Phase 1 randomized, double-blind, placebo-controlled study in healthy adults, with the highest dose (4.0 mg) reducing IGF-1 by 22.5% from baseline and maintaining suppressio…
Source →